A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.
Meningococcal Serogroup B Vaccine
Infections, Meningococcal
Phase 2
An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.
October 2015